Clinical Study to Compare Various Dosing and Titration Guidelines of Insulin Delivered Via V-Go ® in Patients With Type 2 Diabetes Initiating Basal Bolus Therapy in Primary Care Offices (TITRATE)
Clinical Study to Compare Various Dosing and Titration Guidelines of Insulin Delivered Via V-Go ® in Patients With Type 2 Diabetes Initiating Basal Bolus Therapy in Primary Care Offices (Short Title: TITRATE)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Karrie A Hilsinger, BA
- Phone Number: 20116 908-927-9920
- Email: khilsinger@valeritas.com
Study Contact Backup
- Name: Scott Abbott, MS
- Phone Number: 610-739-9832
- Email: Sabbott@valeritas.com
Study Locations
-
-
Pennsylvania
-
Wilkes Barre, Pennsylvania, United States, 18702
- Recruiting
- Geisinger
-
Contact:
- Amy B Cartaya,, MSHA
- Phone Number: 570-214-9544
- Email: abcartaya@geisinger.edu
-
Contact:
- Natacha M Antunes, BS, MPH
- Phone Number: 570-214-6985
- Email: NMANTUNES@geisinger.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria: Patients must meet all of the following inclusion criteria to be eligible for enrollment into the study:
- Age ≥ 21 and ≤80 at time of study enrollment
- Ability to read and understand English
- BMI ≥ 25 kg/m2
- Weight less than or equal to 300 pounds.
- A1C ≥8 but ≤12% (most recent value within 4 weeks of baseline visit)
- Currently using any basal insulin therapy (NPH, Levemir, Lantus) with total daily dose of 30 to 120 units, and where basal dose is greater than the patient's BMI #
- Willing to attend their physician's office for follow-up visits
- Willing and able to understand and sign a written informed consent form (ICF) indicating that they agree to participate and have been informed of all pertinent aspects of the study
- Must be willing to take and record at least 3 glucose measurements per time period (pre-breakfast, lunch, dinner and bed) per week.
- Willing to opt-in into Valeritas Customer Care so that they can receive device support and reminders throughout the study
- Most recent primary care office visit at one of the participating sites.
Exclusion Criteria:Patients presenting with any the following exclusion criteria will not be eligible for enrollment into the study:
- Patient with confirmed Type 1 diabetes and/or patients with a weight greater than 300 lbs.
- Diagnosis of an Autoimmune disease affecting metabolism
- Currently using GLP-1 medications
- Current (within the last 6 months) or planned use of insulin pump for diabetes management or the use of U500 insulin.
- Ongoing participation in any clinical study
- Pregnant, lactating or intending to become pregnant
- Current chronic systemic steroid use
- Prior V-Go use
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: Titration Algorithm A
All patients that are initiated on a V-Go 20 will have a starting bolus dose of 6 clicks (12 units) during the day and all patients who are initiated on a V-Go 30 will have a starting bolus dose of 9 clicks (18 units) during the day.
All patients randomized to Algorithm A will use a fixed starting dose of either 2 clicks per meal (if on the V-Go 20) or 3 clicks per meal (if on the V-Go 30).
|
Initiation and titration of V-Go® using one of two dose titration algorithms to achieve improved A1C at 4 months.
|
|
ACTIVE_COMPARATOR: Titration Algorithm B
All patients that are initiated on a V-Go 20 will have a starting bolus dose of 6 clicks (12 units) during the day and all patients who are initiated on a V-Go 30 will have a starting bolus dose of 9 clicks (18 units) during the day.
All patients randomized to Algorithm B will have 50% of their initial bolus dose given at the largest meal with less bolus insulin at the other meals as noted below:
|
Initiation and titration of V-Go® using one of two dose titration algorithms to achieve improved A1C at 4 months.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
A1C
Time Frame: 4 months
|
Change change in A1C from baseline (randomization) to endpoint (approximately 16 weeks).
|
4 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in glycemic control
Time Frame: 4 months
|
• Difference in the change from baseline (randomization) to end of study visit at 4 months on glycemic control (as measured by A1C level) between the two treatment groups in a pragmatic clinical practice setting
|
4 months
|
|
Patient Treatment Satisfaction
Time Frame: 4 months
|
• Between-group and within-group differences (baseline to end of study visit at 4 months) in patient treatment satisfaction in adult Type 2 patient with diabetes in a real world setting
|
4 months
|
|
Insulin Dose
Time Frame: 4 months
|
• Total daily dose of insulin from baseline to end of study and to evaluate the between-group and within-group differences between the two dosing and titration arms
|
4 months
|
|
A1c at goal
Time Frame: 4 months
|
Percentage of patient achieving a A1C of ≤7%
|
4 months
|
|
7 point glucose profile
Time Frame: 4 months
|
Capture and analyze seven-point glucose profile at baseline and end of study
|
4 months
|
|
Hypoglycemia
Time Frame: 4 months
|
Rates of hypoglycemic events and utilization
|
4 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Ronald Harris, MD, Geisinger Clinic
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CSP-029
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.